Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HRS-5632 in adults at elevated cardiovascular risk with elevated lipoprotein(a)
CTR20253774Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Oct 2025
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-5632 in dyslipidemia, lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Fujian Shengdi Pharmaceuticals. Started Oct 2025; status: active.
02
Drugs
HRS-5632
03
Conditions
dyslipidemialipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on CTR20253774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253774.